Pfizer/J&J Alzheimer’s Drug Should Get Longer Patent Life, Appeals Court Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Bapineuzumab, which was originally a Wyeth and Elan product, is in Phase III testing, and will get eight more months of patent life because of review delays.